INSMED Inc·4

Sep 15, 4:23 PM ET

Schaeffer Orlov S Nicole 4

4 · INSMED Inc · Filed Sep 15, 2025

Insider Transaction Report

Form 4
Period: 2025-09-12
Schaeffer Orlov S Nicole
Chief People Strategy Officer
Transactions
  • Sale

    Common Stock

    2025-09-12$144.60/sh32,091$4,640,35980,890 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-09-1256,5200 total
    Exercise: $23.75Exp: 2030-01-03Common Stock (56,520 underlying)
  • Exercise/Conversion

    Common Stock

    2025-09-12$23.75/sh+56,520$1,342,350112,981 total
  • Sale

    Common Stock

    2025-09-12$145.67/sh30,967$4,510,96349,923 total
  • Sale

    Common Stock

    2025-09-12$147.46/sh6,158$908,05936,461 total
  • Sale

    Common Stock

    2025-09-12$146.57/sh7,304$1,070,54742,619 total
Footnotes (6)
  • [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  • [F2]This is the weighted average sales price representing 32,091 shares sold at prices ranging from $144.06 to $145.05 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  • [F3]This is the weighted average sales price representing 30,967 shares sold at prices ranging from $145.06 to $146.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  • [F4]This is the weighted average sales price representing 7,304 shares sold at prices ranging from $146.08 to $147.06 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  • [F5]This is the weighted average sales price representing 6,158 shares sold at prices ranging from $147.12 to $148.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  • [F6]The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

Documents

1 file
  • 4
    wk-form4_1757967786.xmlPrimary

    FORM 4